Moneycontrol
    Moneycontrol PRO

    Jump to

    • Hope to launch 12-15 new products in next one year: Strides Shasun

    • Book profits on rallies as Nifty is witnessing a ‘Bearish Butterfly’ on the charts

    • Strides Shasun deal could help create bigger franchise: Eris Lifesciences

    • Focus on B2C biz; aim to pare debt from proceeds of Eris Life deal: Strides Shasun

    • Australia biz expanded; rebounded strongly in India & EMs: Strides Shasun

    • Will be vertically integrated formulation company: Strides Shasun

    • Remain bullish about performance overall in FY18: Strides Shasun

    • Sequent Scientific gets CCI approval for Scheme of Arrangement

    • Border tax counter productive for US, may never happen: Strides

    • Regulatory claims on Agila settled, says Strides Shasun

    • Q2 has been a comeback quarter for us in EMs: Stides Shasun

    • Data integrity issues hamper relations with regulators: Strides

    • API biz turnaround likely in 6-8 months: Strides Shasun

    • See margin growing, Australian biz picking up: Strides Shasun

    • Aim to grow biz at 20-25% CAGR: Strides Shasun

    • Hope to complete merger formalities by October end: Shasun

    • Strides Arcolab to buy Aspen's generic biz in Australia

    • Special dividend of Rs 500/share to cost us $525mn: Strides

    • Ailing pharma sector needs uniform drug standards: Ranbaxy

      Given the fact that US gets 35 percent of its drugs from India, the regulator is only doing its job in looking closely at not just India's, but other countries‘ pharma units too, adds Ramesh Adige, former executive director, Ranbaxy.

    • Strides Arcolab arm in JV with Pfenex for biosimilar drugs

      Strides Arcolab‘s subsidiary Agila Biotech has signed a joint venture agreement with US-based Pfenex for developing, manufacturing and commercializing six biosimilar products for the global market

    • Strides Arcolab bets on Agila to drive growth in FY13

      Group CFO of Strides Arcolab TS Rangan tells CNBC-TV18 that the company is betting on Agila to drive growth in FY13.

    • Sale proceeds to help cut debt, repay FCCB: Strides Arcolab

      Strides Arcolab aims to use the funds received through the sale of its Southeast Asian and Australian units to repay foreign currency convertible bondholders and reduce the debt, says group chief executive and vice chairman Arun Kumar.

    • Strides Arcolab eyes 30-35% growth in current year

      In an interview with CNBC-TV18, Arun Kumar, Vice Chairman and MD, Strides Arcolab said Polymyxin is a small molecule, but currently it is in the shortage list of products. He further said the company will grow 30-35% in the current year.

    • Strides, Pfizer to deal post US FDA nod on Oncology unit

      Strides Arcolab received a nod by the US FDA for an Oncology unit in Bengaluru. Arun Kumar, group CEO and vice chairman of Strides Arcolab, in an exclusive interview with CNBC-TV18 shares that the company expects approvals on approximately USD 4-5 billon product filings in the next few weeks.

    • Stride Arcolab targets Rs 2200cr revenue in 2011

      Stride Arcolab has declared its first quarter results. The company's Q1 consolidated net profit was up 2.26% at Rs 40.7 crore versus Rs 39.8 crore. For 2011, he says, “A median EBITDA of 21% is the one we are looking at the increased sales of Rs 2,200 crore.”

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347